Listed life sciences firm secures new Eastern Europe distribution deal
Life sciences business OptiBiotix Health has entered into a three-year distribution agreement in Russia and Kazakhstan.
The York-based firm has partnered with SilvEXPO Ltd to distribute and commercialise its own label CholBiome products containing its cholesterol and blood pressure reducing LP strain.
CholBiome products containing LP have the ability to reduce both cholesterol and blood pressure providing a clinically proven natural product to help reduce cardiovascular risk factors.
Established in the pharmaceutical and nutraceutical industry, SilvExpo was launched following ten years of scientific work, focusing on the export of next generation food supplements to partners in a wide range of countries including Singapore, Armenia, Vietnam, Korea, Malaysia, Bulgaria, France, Russia and Kazakhstan.
The company has now chosen CholBiome as the first product from ProBiotix Health to be offered and introduced into the chain of pharmacies in Russia and Kazakhstan.
The agreement grants SilvExpo non-exclusive distribution rights for CholBiome and extends the sales channel of the CholBiome range of products into the largest Eastern European markets for probiotics.
Russia and Kazakhstan have some of the highest mortality rates in Eastern Europe caused by cardiovascular disease accounting for up to 56% of all deaths, according to the WHO.
Per Rehné, commercial director of OptiBiotix, said: “We are pleased to announce this agreement which extends the sales channel of our CholBiome products into Russia and Kazakhstan where cardiovascular disease are the leading cause of morbidity and mortality. We chose SilvExpo for its knowledge and speed to market and they have shown the ability to grow product sales in challenging markets.
“This agreement is a strategic step to build the distribution sales channel for CholBiome® products in Eastern Europe and we anticipate that the agreement could produce revenues quickly.”
